

FSN & FSCA Ref: 2024FA0007

Date: 30 October 2024

## Urgent Field Safety Notice Product Removal Hemospray Endoscopic Hemostat

For Attention of: Chief Executive / Risk Management / Purchasing/ Recall Coordinator

## Contact details of local representative (name, e-mail, telephone, address etc.)

Cook Medical Europe Ltd.

O'Halloran Road

National Technology Park

Limerick, Ireland

E-mail: European.FieldAction@CookMedical.com

Phone: Please refer to the attached Country Contacts List

For any further information or support concerning the information within this FSN, please contact your local Cook Medical Sales Representative or Cook Medical Europe Ltd.



FSN & FSCA Ref: 2024FA0007

## Urgent Field Safety Notice (FSN) Hemospray Endoscopic Hemostat Risk Addressed by FSN

	Information on Affected Devices				
1. 1. Device Type(s)					
	Hemospray Endoscopic Hemostat is a gastrointestinal haemostasis device supplied sterile.				
1.					
	Hemospray Endoscopic Hemostat				
1.	Primary clinical purpose of device(s)				
	The HEMO-7 & HEMO-10 devices are used for haemostasis of nonvariceal				
	gastrointestinal bleeding. The HEMO-7-EU device is used for haemostasis of				
	nonvariceal upper gastrointestinal bleeding.				
4. Device Model/Catalogue/part number(s)					
	HEMO-7, HEMO-7-EU, HEMO-10				
1.	Affected serial or lot number range				
	Please see the attached Affected Lots List.				

Reason for Field Safety Corrective Action (FSCA)				
2.	2. 1. Description of the product problem			
	Cook Medical has identified that a limited number of nonconforming raw materials were manufactured into certain lot numbers of Hemospray devices and distributed into the field. Use of the devices with these nonconforming raw materials may result in the red activation knob cracking or breaking at the activation knob internal threading while the device is activated, prior to and during use, or after the procedure is complete. This can lead to the activation knob and carbon dioxide cartridge exiting the handle with force.			
2.	Hazard giving rise to the FSCA			
	Potential adverse effects to the user or patient that may occur if they are exposed to a sharp object or projectile include superficial laceration, laceration, infection secondary to laceration, pain, or permanent impairment of a body structure, or may occur without incident and the potential for injury is unlikely. Potential adverse effects to the patient that may occur if there is a significant delay in the hemostasis procedure are additional interventions or medications needed to stabilize the patient, bleeding requiring additional hemostasis, surgical intervention, or death. Additionally, the device failure could be recognizable prior to use and the device would be replaced with an insignificant delay in procedure and the potential for injury is unlikely.			
2.	Probability of problem arising			
	The probability of this incident occurring is 0.3551%.			
2.	Predicted risk to patient/users			
	The predicted individual risk of harm to the user is negligible.			



FSN & FSCA Ref: 2024FA0007

2.	5. Background on Issue				
	There are several lots of nonconforming Hemospray Endoscopic Hemostat devices in the field where use or preparation may result in the activation knob cracking or breaking at the internal threading which may lead to the activation knob and carbon dioxide cartridge exiting the device with force.				
		Type of Action t	to mitigate the risk		
3.	1.				
			Device ⊠ Return Device		
	⊠ Other				
	Please complete the enclosed Reply Form. Where product is indicated as being returned, our Customer Services department will contact you to organize the return and issue you with the relevant Returns Authorization number. <a href="Please">Please</a> include contact details on the Reply Form.				
		Returned Product should be addres Cook Medical EUDC Robert-Koch-Straße, 2 52499 Baesweiler Germany	ssed to:		
		Credit will be provided for the return	ned affected products where applicable.		
3.	2.	By when should the action be completed?	Within five (5) business days of receipt.		
3.	3.	Is customer Reply Required? *	Yes, within five (5) business days of receipt.		
3.	4.	Action Being Taken by the Manufact	urer		
		⊠ Product Removal			
		Affected lot numbers of Hemospray devices are being removed from the market and should be returned to Cook per the attached directions on the Field Action Reply Form.			
3	5.	By when should the action be completed?	Within five (5) business days of receipt.		
3.	6.	Is the FSN required to be communicated to the patient /lay user?	No		



FSN & FSCA Ref: 2024FA0007

	General Information					
4.	1. FSN Type	New				
4.	Further advice or information already expected in follow-up FSN?	No				
3. Manufacturer information     (For contact details of local representative refer to page 1 of a. Company Name     Cook Endoscopy/Wilson		ative refer to page 1 of this FSN)  Cook Endoscopy/Wilson-Cook Medical, Inc.				
	b. Address	4900 Bethania Station Road, Winston-Salem, NC USA				
4.	4. The Competent (Regulatory) Author communication to customers.	ority of your country has been informed about this				
4.	5. Name/Signature	Blair Younts Team Lead, Regulatory Reporting & Field Actions				

## Transmission of this Field Safety Notice

This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred.

Please transfer this notice to other organisations on which this action has an impact.

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.